Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009390 | 0.89 | GPR119 (0.44) | GPR119MAPTKDM4ETHRBHPGD | |
| SCHEMBL18166161 | 0.85 | MAPT (0.40) | GPR119MAPTKDM4ETHRBHPGD | |
| SCHEMBL16698894 | 0.84 | MBOAT4 (0.38) | MBOAT4 | |
| SCHEMBL16049455 | 0.83 | MAP4K4 (0.44) | GPR119MAPTKDM4ETHRBHPGDS | |
| SCHEMBL18153613 | 0.79 | MBOAT4 (0.39) | GPR119MAPTKDM4ETHRBMBOAT4 | |
| SCHEMBL25258371 | 0.78 | GPR119 (0.44) | GPR119MAPTMEN1KMT2APOLB | |
| SCHEMBL19971864 | 0.78 | GRM5 (0.46) | GPR119MEN1KMT2APOLB | |
| SCHEMBL16078096 | 0.77 | MAP4K4 (0.44) | GPR119MAPTKDM4ETHRB | |
| SCHEMBL31605066 | 0.77 | GPR119 (0.42) | GPR119MEN1KMT2AHPGDHPGDS | |
| SCHEMBL16040735 | 0.76 | GPR119 (0.40) | GPR119MAPTKDM4ETHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107454898-B | Ghrelin O-acyltransferase inhibitors | 伊莱利利公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| EP-3068775-B1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | LILLY CO ELI (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3068775-B1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | LILLY CO ELI (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-3068775-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | Eli Lilly and Company (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073281-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073281-A1 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035051-B1 | Ghrelin O-acyl transferase inhibitor | ELI LILLY AND COMPANY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | ELI LILLY AND COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | GPR119 18/4885MAPT 1378/4885KDM4E 961/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | GPR119 18/4885MAPT 1378/4885KDM4E 961/4885 |
| US-20150133474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITOR | MBOAT4, DGAT1, MOGAT2 | GPR119 24/4885MAPT 1343/4885KDM4E 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.